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ABSTRACT
Johnson, Hunter C. M.S.B.M.E., Purdue University, May 2020. Integrative Click
Chemistries for Tuning Physicochemical Properties of Cancer Cell-Laden Hydrogels.
Major Professor: Chien-Chi Lin.
The pancreas is a vital organ that secretes key metabolic hormones and digestive
enzymes. In pancreatic ductal adenocarcinoma (PDAC), one of the leading causes
of cancer-related death in the world, limited advances in diagnosis or therapies have
been made over decades. Key features of PDAC progression include an elevated
matrix stiffness and an increased deposition of extracellular matrices (ECM), such as
hyaluronic acid (HA). Understanding how cells interact with components in the tumor
microenvironment (TME) as PDAC progresses can assist in developing diagnostic
tools and therapeutic treatment options. In recent years, hydrogels have proven to
be an excellent platform for studying cell-cell and cell-matrix interactions. Utilizing
chemically modified and naturally derived materials, hydrogel networks can be formed
to encompass not only the components, but also the physicochemical properties of
the dynamic TME. In this work, a dynamic hydrogel system that integrates multiple
click chemistries was developed for tuning matrix physicochemical properties in a
manner similar to the temporally increased matrix stiffness and depositions of HA.
Subsequently, these dynamic hydrogels were used to investigate how matrix stiffening
and increased HA presentation might affect survival of PDAC cells and their response
to chemotherapeutics.
11. INTRODUCTION
1.1 The pancreas and PDAC
The pancreas plays a vital role in energy consumption and regulation of metabol-
ism [1]. It consists of two functionally and morphologically distinct components,
namely, the exocrine and endocrine pancreas [1]. The exocrine tissues are made
up of acinar and ductal cells, of which the acinar cells produce digestive enzymes
and release them into pancreatic ducts [1]. The endocrine tissues are comprised of
cells that produce and secrete specific hormones responsible for regulation of blood
glucose levels [1]. PDAC and diabetes are two of the most common and devastating
diseases associated with the exocrine and endocrine pancreas, respectively [1]. After
cardiovascular diseases, cancers are the second-most leading cause of death in America
[2]. Of the estimated 57,770 new pancreatic cancer incidences in 2019, there is an
estimated 45,750 deaths [2]. Pancreatic cancer incidences accounted for 3% of the
total incidences in 2019, while the associated deaths were 7 and 8% for male and
female patients, respectively [2]. The incidence rates for pancreatic cancers continue
to increase, while the survival rates are among the lowest of all cancers [2].
1.1.1 Treatments of PDAC
Therapeutic failures can be attributed to the PDAC microenvironment, which is
regulated by not only the tumor cells, but also cells in the stromal tissue, includ-
ing pancreatic stellate cells, myofibroblasts, inflammatory fibroblasts, and immune
cells [3]. Additionally, the cell-type of origin dictates the phenotype of the tumor [4].
For example, when tumors originate from ductal cells, high-grade pancreatic intraep-
ithelial neoplasia (PanIN) lesion growth is accelerated when compared to tumors orig-
2inating from acinar cells, in which metaplasia and low-grade PanIN lesions are more
common [4]. Furthermore, differing biologies result in cells with varied innate epithe-
lial or mesenchymal characteristics [5]. Small molecules, such as non-coding RNA and
micro RNA, also play a significant role in PDAC chemoresistance, as well as over-
expression of integrins that regulate cellular functions such as epithelial-mesenchymal
transition (EMT) [6].
The current standard-of-care for early-stage PDAC is curative-intended resection
and adjuvant therapy [7]. while the standard-of-care for advanced-stage and pal-
liative treatment of PDAC is gemcitabine (GEM) [8, 9]. In other gastrointestinal
tract cancers, such as esophagus and gastric cancer, neoadjuvant therapies and peri-
operative multimodal therapies have significantly improved the outcome of patients
with resectable tumors; thus, these therapies may prove beneficial in the treatment
of PDAC [7]. Another treatment option for resectable tumors, for BRCA-positive
PDAC, is poly-ADP-ribose polymerase inhibitors [10]. Unfortunately, early diagnoses
and treatment is unlikely as only 10-15% of patients are diagnosed when the tumor
is resectable [9]. Therefore, there is a need to establish greater understanding of the
progression of PDAC, namely, through the interactions of cells with other cells and
cells with their changing environment for improved diagnostic and even therapeutic
tools.
1.1.2 Extracellular matrix (ECM) of PDAC
The ECM is a three-dimensional (3D) network of highly dynamic and hetero-
geneous biomolecules that regulate many cellular functions, including migration,
spreading, differentiation, and proliferation [11, 12]. Dysregulation of ECM remod-
eling can result in structural, compositional, and functional defects that eventually
lead to pathological events such as fibrosis and invasive cancers [11]. In recent years,
biomimetic materials have enabled the recapitulation of critical ECM properties (e.g.,
stiffness and cell adhesion sites) in vitro. Certain integrin ligands, such as fibronectin
3derived arginine-glycine-aspartic acid (RGD), provide the ability for cell attach-
ment [13, 14] while other motifs (e.g., glycine-phenylalanine-hydroxyproline-glycine-
glutamic acid-arginine; GFOGER) direct cellular differentiation [13]. In addition
to biochemical cues, biophysical properties of ECM (e.g., stiffness, stress-relaxation)
also regulate stem cell phenotype and fate [15]. For example, it was discovered that
matrix stress-relaxation promote spreading and differentiation of mesenchymal stem
cells [16].
1.1.3 Mechanics of PDAC stromal tissues
Pancreatic cancer is among the stiffest solid carcinomas in humans marked with
an extraordinary desmoplastic reaction [17]. Increases in collagen-I deposition and
fiber thickness, by cells such as cancer associated fibroblasts and activated pancreatic
stellate cells (PSCs), promote cell survival, proliferation and migration [17, 18]. Ad-
ditionally, alignment of collagen-I fibers lead to increases in matrix stiffness, which
potentially leads to increased metastatic characteristics [17]. The stiffness of healthy
pancreatic tissue, PanIN, and PDAC, as well as several PDAC cell lines, were de-
termined via atomic force microscopy as shown in Figure 1.1. Another consequence
of the dense stroma is the abundance of various ECM molecules and their ability to
retain water, which increases interstitial fluid pressure [18]. All of these factors are
believed to promote EMT and increased drug resistance [17,18].
1.1.4 Biochemical compositions of PDAC stromal tissue
Tumor-derived ECM is biochemically distinct from and typically stiffer than ECM
in healthy tissue [17, 20]. The altered state of the ECM creates a niche for cancer
stem cells (CSCs), which have self-renewing capabilities, tumor-initiating capacities,
and increased chemoresistance [20]. Depending on the cell of origin [4] and the bi-
ology of the patient (e.g. increased or decreased presence of cell-surface proteins
relevant to disease progression) [5], tumors display varied phenotypes, including their
4Fig. 1.1. (left) PDAC cell stiffness [19] and (right) pancreatic tissue
stiffness from healthy to diseased states [17]
innate epithelial or mesenchymal characteristics. Variables such as matrix stiffness
and quantities of cell-surface proteins and extracellular matrix components result in
increased chemoresistance of PDAC tumors, making them increasingly difficult to
treat [6].
Recently, it is suggested that hyaluronan (HA), a linear glycosaminoglycan present
in the majority of tissues, creates a favorable environment for cancer progression [21].
For example, when HA binds to cluster of differentiation 44 (CD44), multiple recep-
tor kinases are stimulated in HCT116 colon cancer cells, which leads to increased
cell adhesion, proliferation, invasion, and overall survival [22]. HA also binds to toll
like receptor 4, which promotes epithelial repair in radiation injury models and me-
diates normal growth of epithelial stem cells in the colon and intestine [22]. HA also
binds to receptor for HA-mediated motility (RHAMM) [21]. HA binding to CD44
and RHAMM mediates cellular processes such as cell adhesion, migration, and sur-
vival [21]. RHAMM and CD44 also function as co-receptors for activating transmem-
brane tyrosine kinases [21]. PDAC is characterized by dense desmoplastic stroma and
increased accumulation of HA (Figure 1.2). Increased HA presence correlates to poor
prognosis in PDAC mouse models [21]. An upregulation of secreted HA synthases,
through tumor-stromal cell interactions, results in an increased abundance of HA in
5PDAC and this contributes to many malignant characteristics such as unregulated
proliferation, migration, invasion and angiogenesis [20, 22]. This abundance of HA
also could act as a physical barrier through sheer amount of the molecule and its
ability to retain water, increasing interstitial fluid pressure, decreasing the efficacy
of chemotherapeutics [18, 20]. Therefore, blocking HA-initiated signaling could facil-
itate therapies for PDAC by reducing malignant characteristics. This approach has
been attempted in colon cancer, where HA-binding interactions were blocked with a
12-mer peptide [21].
Fig. 1.2. (A, B) IHC staining (red) of overexpressed HA in pancreatic
tumors; (C, D) non-stained sections of pancreatic tumors [23]
1.2 Hydrogels for 3D cell culture
Cells are influenced by substrate mechanics, namely, the stiffness of the substrate.
Conventional culture methods rely on statically stiff 2D tissue culture plastics (TCPs).
However, the ECM is a 3D structure [11, 12]. Cell behaviors in 2D environments do
not necessarily recapitulate the behaviors of cells in a more natural, that is 3D, envi-
ronment. Thus, researchers have shifted from cell culturing in 2D and moved towards
3D, to better understand how cells would behave in their natural environment. For
example, human mesenchymal stem cells (hMSCs) were cultured on TCPs or in PEG-
6gelatin hydrogels and there were distinct morphological differences between the 2D
and 3D [24]. Additionally, depending on the stiffness of the PEG-gelatin hydrogels,
there were morphological differences in cultured hMSCs [24].
1.2.1 Static elastic hydrogels for cell culture
Mechanically static and elastic hydrogels have been utilized to study many cell
types and specific cell processes. For example, the effects of chain-growth vs. step-
growth photopolymerized hydrogels was explored with hMSC culture and it was found
that there was more spreading and increased viability in the step-growth polymerized
networks [25]. The influence of pancreatic stromal cells on PDAC spheroids were in-
vestigated utilizing methylcellulose-based hydrogels [26]. Matrigel was utilized to fab-
ricate organogenesis models for the study of PDAC [27]. PEG-based hydrogels were
fabricated to investigate the viability of radical-sensitive MIN6 cells [28]. Additionally,
the influence of β-cyclodextrin [29] and soluble tyrosine [30] on MIN6 insulin-secreting
capacities were investigated in PEG-based hydrogels. When natural and synthetic
scaffolds with similar storage moduli were utilized for cholangiocyte culture, they
had comparable cyst formation [31]. Full-thickness skin layers were synthesized via
fibroblast encapsulation and keratinocyte seeding on pectin-peptide hydrogels [32].
Electrospun methacrylate-HA (Me-HA) hydrogels were exploited to culture meniscal
fibrochondrocytes and stiffer Me-HA networks promoted greater collagen-I deposi-
tion and migration into meniscal tissue, in vivo [33]. Gelatin-HA hydrogels enabled
endothelial progenitor cells to synthesize complex vascular networks [34].
1.2.2 Viscoelastic hydrogels for cell culture
Viscoelastic hydrogels have also been utilized to study a wide range of cell be-
haviors. Naturally, the ECM is viscoelastic [16], so there has been increasing at-
tention in hydrogels with stress-relaxing capabilities. Low molecular weight (MW)
polyacrylamide (PAA) was covalently crosslinked and contained entrapped high MW
7PAA, creating dissipative (i.e. stress-relaxing) hydrogels for 3T3 cell culture [35]. It
was shown that 3T3 cells cultured in hydrogels that were stiffer and/or had greater
stress-relaxation exhibited higher densities of paxillin patches, when compared to 3T3
cells in softer and/or less stress-relaxing hydrogels [35]. Hydrogels were formed for
3T3 cell culture with varied levels of stiffness and viscoelasticity via manipulating
the MW of alginate and concentration of PEG-spacers [16]. Spreading and pro-
liferation of encapsulated 3T3 cells increased as a function of the concentration of
RGD and viscoelasticity [16]. PEG hydrogels with permanent strain-promoted azide-
alkyne cycloaddition crosslinks and physical dibenzocyclooctyne-dibenzocyclooctyne
crosslinks, which introduced viscoelasticity, were utilized to culture chondrocytes and
it was found that stiffer and more viscoelastic hydrogels promoted proliferation and
chondrogenic ECM deposition [36]. PEG hydrogels formed with reversible boronate
bonds created a viscoelastic environment in which hMSCs were cultured [37]. It was
found that cell-ECM interactions increased as the rate of relaxation increased [37].
Interpenetrating networks formed with reconstituted basement membrane proteins
and alginate were utilized to culture MDA-231 cells and there was an increase in
matrix maneuvering throughout higher plasticity interpenetrating networks [38].
1.2.3 Mechanically dynamic hydrogels for cell culture
Although there have been great efforts in understanding cellular behaviors in static
3D environments, the behavior of cells in static environments does not recapitulate
the natural ECM, as it is constantly undergoing changes [11, 12]. One key aspect
of the dynamic nature of the ECM lies within the increase (or decrease) in stiffness
due to deposition or degradation of ECM-proteins, like collagen-I [11]. In lieu of
this, mechanically dynamic hydrogel systems are increasingly in demand for greater
mimetics, leading to heightened understanding of how cells truly behave in their
natural environment.
8For example, valvular interstitial cells (VICs) were cultured in initially soft PEG-
peptide hydrogels and some were dynamically stiffened after 3-days to separate the
effects of morphology and modulus [14]. In soft hydrogels, VICs exhibited greater
levels of αSMA stress fibers and associated mRNA, which is characteristic of myofi-
broblasts [14]. In stiffened hydrogels, VICs were deactivated to a quiescent fibroblast
phenotype, which suggests that VIC phenotype is directed by matrix stiffness and is
independent of morphology [14].
In another example, cardiac fibroblasts were cultured in statically soft or stiff
hydrogels, as well as dynamically stiffened hydrogels, which mimicked the stiffness
of a healthy or fibrotic heart (i.e. soft or stiff, respectively) [39]. When cardiac fi-
broblasts were cultured in static hydrogels, nuclear factor of activated T-cells was
localized in the cytoplasm, whereas when they were cultured on dynamically stiff-
ened hydrogels, nuclear factor of activated T-cells was localized in the nucleus within
6-hours [39]. These findings indicate that dynamic mechanical property changes can
initiate mechanotransduction pathways that would otherwise be missing in static envi-
ronments [39]. In a separate study, mammary epithelial cells were cultured in Me-HA
hydrogels that were dynamically stiffened to mimic the gradual matrix stiffening that
occurs during breast cancer progression; the soft and stiffened hydrogels mimicked
healthy and diseased tissue, respectively [40]. In both conditions mammary epithelial
cells formed spheroids, but in the stiffened condition they lost epithelial characteristics
and adopted mesenchymal morphologies [40]. Stiffness-mediated signaling appeared
to be modulated via Twist1, TGF-β and YAP activation; culture-time prior to stiff-
ening, as well as the degree of stiffening, affected the rate of change [40]. In another
study, MCF10A (non-malignant mammary epithelial cells) were cultured in alginate
hydrogels for 14-days and allowed to form acini prior to dynamic stiffening [41]. As a
result of stiffening, these cells invaded from and proliferated in the mammary acini,
correlating well with the knowledge that MCF10A cells cultured in stiffened environ-
ments lose epithelial characteristics and become invasive [41]. The cells maintained
cell-cell contacts while migrating away from the acini, while P13K and Rac1 inhi-
9bition via small molecules effectively reduced the quantity and size of invasive acini
post-stiffening [41].
In addition to light or charge-based reactions, enzymatic reactions were utilized to
fabricate PEG-peptide hydrogels, which were used to encapsulate COLO357 cells in
an initially soft environment [42]. Dynamic stiffening was accomplished via mushroom
tyrosinase (MT) [42]. A stiffened environment led to significantly smaller COLO357
spheroids, suggesting that spheroid size reductions are caused by dynamically stiff-
ened environments [42]. In a separate study, reversibly soft/stiff PEG-peptide hydro-
gels were utilized to encapsulate COLO357 or hMSCs [43]. Spreading and growth
of hMSCs were increased in softened hydrogels, when compared to stiffened hydro-
gels [43]. In stiff and stiffened hydrogels, COLO357 exhibited drug resistance, while
these characteristics were not present in statically soft and less present in the softened
hydrogels [43]. Dynamic PEG-peptide hydrogels were utilized to encapsulate PSCs
to investigate the effects of matrix stiffening on PSC activation, namely, into myofi-
broblastic phenotypes [44]. MT-mediated stiffening resulted in increased expression
of αSMA and HIF-1α, suggesting activation into myofibroblastic phenotype [44].
1.2.4 Prior examples of biomimetic hydrogels for cell culture
Biomimetic hydrogels can be generally defined as systems that contain tunable
matrix mechanics and permeability, integrin-binding ligands, and matrix degradabil-
ity [45], although not all contain each of these properties. These hydrogels can
be formed taking advantage of various crosslinking methods such as: chain-growth,
step-growth, or mixed-mode photopolymerization, as well as enzymatic reactions and
supramolecular interactions [45]. The purpose of biomimetic hydrogels is to enable
the study of how cells interact with their environment and with other cells, in systems
that are emulative of their natural niches.
All biomimetic hydrogels should contain integrin-ligands and matrix metallopro-
teinase (MMP)-degradable sites. For example, PEG-peptide hydrogels were utilized
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to culture hMSCs and MIN6 [28] or MIN6 cells alone [30]. RGD-tagging was exploited
to promote cell attachment in otherwise bio-inert systems [30] and in Me-HA hydro-
gels utilized to culture meniscal fibrochondrocytes [33]. Other PEG-based hydrogels
were dynamically stiffened and included laminin-111 [46], HA, [47], or mechanical
matching of hydrogels to healthy and diseased tissue [39].
1.3 Gelation mechanisms
Hydrogels are attractive cell-culture platforms due to their wide range of reaction
modes and chemistries of gelation. Commonly used crosslinking methods include, but
are not limited to, chain-growth, step-growth, and mixed-mode photopolymerization,
enzyme-mediated or click-chemistry-mediated polymerization, and supramolecular as-
sembly [45]. Additionally, hydrogel crosslinking can be initiated with light (either UV
or visible), or induced by temperature changes, ionic interactions, or enzymatic reac-
tions. With a plethora of gelation modes and chemistries, hydrogels are easily tuned
to fit specific needs, such as elastic, storage and/or loss moduli, tethering of bioac-
tive molecules, and degradability. Advantages of hydrazone bonds (a click-chemistry
between aldehyde and hydrazide moieties) lies within their ability to impart more
viscoelasticity into the system and the lack of necessity for an initiator [34, 48]. A
disadvantage is the lack of spatiotemporal crosslinking control [45].
1.3.1 Thiol-norbornene gelation for cell culture
Thiol-norbornene crosslinking, shown in Figure 1.3, has been widely utilized for
biomimetic hydrogels due to its fast reaction rates, cytocompatibility, spatiotempo-
ral control of crosslinking kinetics, and facile tethering of bioactive molecules [49].
Conventionally, thiol-norbornene gelation is initiated by UV light (wavelength = 365
nm) irradiation. Alternatively, Eosin-Y can be used as the sole-photoinitiator for vis-
ible light initiated gelation (400 – 700 nm) [28, 30, 49, 50]. With long-wave UV-light
and a photo-initiator (such as lithium phenyl-2,4,6-trimethylbenzoylphosphinate or
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LAP), primary networks of crosslinked thiol-norbornene hydrogels were utilized for
cell-culture [14,25,32,51–53]. Another utilization of the thiol-norbornene photo-click
reaction is immobilization of biomimetic peptides that enable cell-attachment and/or
MMP-degradation [42].
Fig. 1.3. Photo-click thiol-norbornene crosslinking
1.3.2 Tetrazine-olefin click chemistry
The inverse electron Diels-Alder addition (iEDDA) click-chemistry takes place be-
tween 1,2,4,5-tetrazines (Tz) and olefins (e.g., norbornene or NB) [54]. Due to iEDDA
biorthogonality (i.e. biological activity of biologics, such as DNA and enzymes,
undisturbed), high-reaction speed, and hydrolytic stability [54] these reactions are
becoming increasingly popular. Tz ligation with trans-cyclooctyne (TCO) permitted
temporal control of hydrogel stiffness and biomarker presentation for encapsulated
hMSCs [47]. A hydrophilic polymer with unreacted Tz formed a primary network
with thiolated HA HA-SH, after which the network could be stiffened via TCO-
modified HA (HA-TCO) or cell-attachment could be increased via TCO-modified
RGD (RGD-TCO) [47]. In another 3D study, PEG-gelatin hydrogels formed via click
Tz-NB reactions encapsulated hMSCs [21]. As the stiffness of hydrogels increased,
the amount of hMSC spreading decreased [21]. The Tz-NB reaction schematic can
be seen in Figure 1.4.
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Fig. 1.4. Click tetrazine-norbornene crosslinking
1.3.3 Hydrazone hydrogels
Hydrazone crosslinked hydrogels are injectable, self-healing, and stimuli responsive
(e.g., pH or redox triggers) [34,55]. The hydrazone reaction schematic can be seen in
Figure 1.5. They have been predominantly used to investigate the effects of stress-
relaxation on cells in culture. For example, RGD-modified alginate substrates were
utilized for culturing mouse myoblasts in 2D [56]. In this study, covalent hydrazone
crosslinks were formed with oxidized alginate and adipic acid dihydrazide, and ionic
crosslinks were formed with divalent calcium ions and alginate [56]. By manipulating
the density of covalent or ionic crosslinks, this group was able to create hydrogels
with varied elastic and viscoelastic (i.e. stress-relaxation) profiles, respectively [56]. In
another example, A549 cells encapsulated in oxidized alginate and propionohydrazide-
modified PEG hydrogels were viable after 24-hours [48]. In another 3D study, gelatin-
and oxidized dextran-based hydrogels loaded with endothelial colony-forming cells
were subcutaneously injected into backs of mice [34]. The encapsulated and injected
endothelial colony-forming cells were able to form complex vascular networks in vivo
[34].
Fig. 1.5. Click aldehyde-hydrazide hydrazone crosslinking
13
1.4 Rationale for the thesis
To recapitulate the natural progression of healthy to diseased pancreatic tissue
(i.e. HA presence and increase in matrix stiffness), prior studies have utilized gelatin-
HA hybrid hydrogels that can be dynamically stiffened to culture PDAC cells [51,52].
In these examples, however, HA was a part of the primary hydrogel network and only
matrix stiffness was dynamically altered via enzymatic reactions [51, 52]. As previ-
ously stated, in the natural PDAC progression, there is an increase in matrix stiffness
and an accumulation of secreted HA [17, 18]. In an effort to improve the design of
a dynamic hydrogel system that recapitulates a stiffening matrix with accumulation
of HA deposition, this work explores the use of chemically modified HA to stiffen a
cell-laden hydrogel.
14
2. OBJECTIVES
To gain an understanding of how synergistic increase in matrix stiffness and accu-
mulation of HA affect PDAC cells in 3D culture, soft PEG-gelatin hydrogel networks
were formed, followed by dynamic stiffening with chemically modified HA. The pri-
mary PEG-gelatin hydrogels were crosslinked by either thiol-norbornene or aldehyde-
hydrazide click-chemistry, whereas stiffening was accomplished by chemically modified
HA via tetrazine-norbornene or aldehyde-hydrazide click-chemistry. After establish-
ing a dynamic hydrogel platform, initially formed with thiol-norbornene crosslinks and
stiffened by hydrazone crosslinks, the system was exploited for PDAC cell culture, in
which the viability and metabolic activity where characterized via live/dead staining
and alamarblue, respectively, and encapsulated cells were treated with chemothera-
peutics. This system was developed to gain understanding into the synergistic effects
of matrix stiffening and increased presence of HA on PDAC cells. To achieve these
goals, the following objectives were proposed:
• To integrate orthogonal click-chemistries for forming PEG-gelatin hydrogel sys-
tems with independently tunable mechanical and biological properties.
Specifically, hydrogels were crosslinked via thiol-norbornene, tetrazine-
norbornene, or aldehyde-hydrazide click-chemistries. In one network, norborn-
ene was in excess, relative to thiol, for tetrazine-based stiffening. In another
network, hydrazide was in excess, relative to aldehyde, for aldehyde-based stiff-
ening.
• To utilize tunable PEG-gelatin hydrogel system for encapsulation of PDAC cells
to study the synergistic effect of stiffening and accumulating-HA on PDAC cell
fate.
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Specifically, cell viability, spheroid size, and morphology of encapsulated PDAC
cells in stiffened and HA-accumulating matrices were monitored via live/dead
stained cell images. Additionally, relative metabolic activities of PDAC cells,
before and after stiffening, were assessed via alamarblue reagent. Chemother-
apeutic efficacy of gemcitabine (GEM) was also explored in response to the
stiffened and HA-accumulating matrices.
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3. MATERIALS AND METHODS
3.1 General Materials
Type B gelatin (bloom 225) was purchased from Electron Microscopy Sciences.
Carbic anhydride (CA), carbohydrazide (CDH), and 1-ethyl-3-(3-dimethylamino
propyl)carbodiimide HCl (EDC) were purchased from Acros Organics. Sodium
hyaluronate (14.8 and 74 kDa) were purchased from Lifecore Biomedical. Heparin
sodium salt was purchased from Celsus Laboratories. Tetrazine-amine (Tz-amine)
was purchased from Click Chemistry Tools. N-hydroxysuccinimide (NHS) and N,N-
diisopropylethylamine (DIEA) were purchased from Tokyo Chemical Industries. Hy-
droxy benzotriazole (HOBt) was purchased from Oakwood Chemical. Alamar blue
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were pur-
chased from Fisher. Poly(ethylene glycol)-tetra-propionaldehyde (PEG4pAld) and
poly(ethylene glycol)-tetra-thiol (PEG4SH), shown in Figure 3.1,were purchased from
Layson Bio. Viability (live/dead) kit was purchased from Biotium. Rabbit anti-CD44
antibody and goat anti-rabbit IgG-TR were purchased from Ray Biotech and Santa
Cruz Biotech, respectively. N2 and N21 MAX media were purchased from R and
D Systems. High glucose DMEM and DMEM/ham’s F-12 50/50 were purchased
from GE Healthcare and Corning, respectively. DPBS, fetal bovine serum (FBS) and
100 antibioticantimycotic were purchased from Corning. 1,9-dimethyl-methylene blue
(DMMB) zinc chloride and all other chemicals were purchased from Sigma-Aldrich,
unless otherwise noted.
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Fig. 3.1. Structure of PEG4SH (A) and PEG4pAld (B)
3.2 Macromer Synthesis and Characterization
8-arm poly(ethylene glycol) (PEG8NB) was synthesized and characterized follow-
ing published procedures [42, 57]. Gel(B)NB was synthesized following a published
procedure [25]. Gel(B)NB substitutions were characterized via Fluoraldehyde assay
using unmodified gelatin with known concentrations as a standard. In Figure 3.2, a
synthesis schematic of Gel(B)NB is shown.
Gel(B)NB-CDH was synthesized with the following procedure. First, Gel(B)NB
was dissolved in 50 mL PBS, which was kept warm and stirred via rotovap. Gelatin
solution was then moved to 45oC oil bath and CDH was added to the solution and
mixed until dissolved. EDC and HOBt were dissolved in 13 mL DI-H2O and amine-
free dimethylformamide (DMF) (1:1 v/v). Once dissolved, the EDC and HOBt mix-
ture was added to the gelatin solution. Subsequently, the pH was adjusted to 5 and
the reaction was allowed to occur for 24-hours at 45oC. After the 24-hours, the so-
lution was transferred to a dialysis membrane of 12-14 kDa molecular weight cut-off
(MWCO), where it underwent dialysis for 3-days at 40oC (first day 0.1 M NaCl added
and 2nd and 3rd day drops of HCl were added). After dialysis, the solution was frozen
and lyophilized. Functionalization of CDH was characterized via 2,4,6-trinitobenzene
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Fig. 3.2. Synthesis schematic of Gel(B)NB
sulfonic acid (TNBSA) assay, comparing Gel(B)NB-CDH to a standard curve created
from ADH. In Figure 3.3, a synthesis schematic of Gel(B)CDH is shown.
Fig. 3.3. Synthesis schematic of Gel(B)CDH
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Heparin-tetrazine (Hep-Tz) was synthesized by dissolving, at room temperature
with stirring, heparin sodium salt (16.3 kDa) in 15 mL ddH2O. Subsequently, 5-fold
excess EDC and NHS were dissolved in the heparin solution. Prior to Tz-amine HCl
salt addition, there was a 30-minute activation of carboxylic acids via EDC/NHS.
Separately, 5-fold excess Tz-amine HCl salt was dissolved at room temperature, with
stirring and protection from light, in 5 mL ddH2O. Once dissolved, the heparin and
Tz-amine solutions were combined stirred in the dark for 16-hours. Dialysis in ddH2O,
with a 3500 MWCO cellulose membrane, was performed at room temperature in the
dark for 2-days. After dialysis, the product was frozen and lyophilized, while being
protected from light. HA-tetrazine (HA-Tz; 14.8 or 74 kDa) was synthesized in a
similar manner, adjusting the concentrations of EDC, NHS and Tz-amine HCl salt to
carboxylic acids available in HA compared to heparin. To quantify the conjugation of
Tz-amine to heparin, a Synergy HT microplate reader at 523 nm was used to create
a standard curve of Tz-amine HCl salt and compared to Hep-Tz or HA-Tz solution.
Four-arm PEG-tetrazine (PEG4Tz) was synthesized by first dissolved PEG4ASA
(10 kDa) in 2 mL amine-free DMF. Subsequently, HATU was added to the solution
and stirred for 10-minutes at room temperature. Simultaneously, Tz-amine HCl salt
was dissolved in 500 µL amine-free DMF and stirred for 20-minutes. After the 10-
and 20-minutes were complete, the two solutions were mixed together and 5-fold
excess DIEA was added to the reaction vessel. The final solution is stirred and
protected from light for 16-hours. After 16-hours, the solution is transferred to a
3500 MWCO dialysis membrane and dialyzed for 2-days, still protecting from light.
Following dialysis, the product was frozen and lyophilized prior to quantification of
Tz substitution. PEG4Tz was similarly quantified to Tz conjugation in HA-Tz and
Hep-Tz.
For oxidized-dextran (oDex) synthesis, first NaIO4 was dissolved in 200 mL ddH2O
and the solution was protected from light. The amount of NaIO4 dissolved varied
depending on the desired degree of oxidation. Dextran (100 kDa) was then dissolved
into the NaIO4 solution and left stirring overnight while protected from light. The
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next morning, the solution was transferred to a 12-14 kDa MWCO dialysis mem-
brane and dialyzed for 3-days. After dialysis, the solution was frozen and lyophilized
to collect product. Theoretical functionalization was ascertained via concentration of
diols that could be ring-opening oxidized. For oxidized-HA (oHA; 14.8, 74, or 740
kDa) synthesis, the procedure was the same as oDex. The concentration of carboxylic
acids per weight percent did not change with molecular weight, thus, the amount of
NaIO4 used for varied degrees of oxidation was kept constant for different MW oHA
synthesis.
Tetrazine modified macromers (TMMs) are shown in Figure 3.4 and oxidized
molecules are shown in Figure 3.5.
Fig. 3.4. Synthesis schematics for PEG4Tz (A), Hep-Tz (B) and HA-Tz (C)
3.3 Hydrogel Fabrication and Characterization
Hydrogels were initially crosslinked with two different methods: (1) photo-click
thiol-norbornene (both UV and visible light) and (2) hydrazone. For hydrogels formed
via UV-light, gel precursors were prepared with desired concentrations of LAP, NB-
and SH-containing macromers and mixed well via vortexing. Subsequently, pre-mixed
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Fig. 3.5. Synthesis schematics for oDex (A) and oHA (B)
precursor solution was pipetted between two glass slides, separated by 1 mm thick
spacers, and exposed to 5 mW/cm2 365 nm light for 2-minutes via Blak-Ray XX-15M
UV Bench Lamp.
For hydrogels formed via visible light, gel precursors were prepared in a similar
manner to that described above. Subsequently, pre-mixed precursor solution was
pipetted between two glass slides, separated by 1 mm thick spacers, and exposed to
70 kLux visible light for 5-minutes via AmScope Cold-Light Source Haloid Lamp.
Hydrogels formed via spontaneous hydrazone crosslinks were prepared by initially
creating two precursor solutions that would leave excess CDH (and NB) in the hy-
drogel: (1) Gel(B)NB-CDH and PBS and (2) oHA. Molds were then placed on glass
slides and the negative space was coated with plasma oxygen. Due to the small vol-
ume of (2) used in each gel, (2) was pipetted into the negative space within the mold
followed by (1). Gelation begun upon contact, so there was very little working time.
In efforts to homogenize the mixture, gentle swirling of the pipette tip was employed
starting from the outside and working in. Binder clips were then placed on each end
of the glass slide with a mold and the entity was inverted and placed within a hu-
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midifying chamber with a damp piece of cloth to ensure hydration. These gels were
given 30-minutes to form completely.
Each hydrogel was prepared with ideal dimensions of 1 mm thickness and 8 mm
diameter. After fabrication, each hydrogel was given at least 1-hour to swell to equi-
librium in DPBS + 1% P/S, prior to rheological characterization. Generally, stiffen-
ing was initiated immediately following pre-stiffened rheological characterization and
lasted for 24-hours. In a few cases, stiffening endured for longer than 24-hours.
Quantification of G’ and G” (shear/storage and loss modulus, respectively) for
fabricated hydrogels was accomplished via parallel plate, strain sweep rheometry on
Bohlin CVO 100 Digital Rheometer. Strain ranged from 0.1-5%, at an oscillating
frequency of 1 Hz, over the course of 100 seconds and testing was conducted at room
temperature. The first few data points were removed from analysis to allow the
stabilization of the rheometer and the values were averaged to obtain G’ and G”.
3.4 Cytotoxicity and Alamarblue assays
Cytotoxicity studies for HA-Tz and oHA were conducted in 2D. PANC-1 were
plated in a 96-well plate at 50,000 cells/mL and allowed to attach and grow for
2-3 days. Subsequently, varied concentrations of soluble, chemically-modified HA
were added to wells in quadruplicate. Soluble HA was kept in solution for 24-hours.
Subsequently, media + MTT reagent was added to each well for a specified amount
of time before the media + MTT reagent was carefully aspirated. Metabolic product
was solubilized in dimethyl sulfoxide (DMSO) and mixed well (via pipette) before
transfer to a separate well plate for absorbance reading at 590 nm via Synergy HT
microplate reader. DMSO was used as a blank.
Alamarblue was conducted in 3D for encapsulated cells. For this procedure, all
solutions and materials were protected from light. First, a solution (i.e. alamarblue
solution) of 1-part alamarblue reagent and 9-parts high glucose DMEM media (+10%
FBS and 1% P/S) was created. Second, encapsulated cells were transferred to new
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wells prior to addition of alamarblue solution. The encapsulated cells were maintained
in alamarblue solution for a number of hours (varied depending on cell type and
density). Subsequently, encapsulated cells were transferred to new wells and refreshed
with new media. The alamarblue solution was then carefully mixed, in each well, and
a portion was transferred to a new well plate for fluorescence readings at excitation
and emission wavelengths of 560 and 590 nm, respectively, via Synergy HT microplate
reader. Pure alamarblue was used as a blank. Fluorescence values were normalized
to non-treated encapsulated cells.
3.5 Cell maintenance and encapsulation
PANC-1 cells were cultured on TCPs in high glucose DMEM with 10% FBS and
1% P/S added for additional growth factors and sterility, respectively. Media was
refreshed every 2-3 days, according to the need. The cells were allowed to grow until
they reached confluence of around 70% prior to passaging and/or encapsulating.
For encapsulations, all hydrogel and post-modification materials were sterile-
filtered through 22 µm filters. Additionally, some materials, namely modified gelatin
and HA, were further sterilized with germicidal, mid-wave UV (i.e. 254 nm).
Encapsulating PANC-1 in visible-light crosslinked hydrogels was accomplished in
syringes with their tops cut off. The volume of each hydrogel was 25 µL and the
encapsulation density was 1,000,000 cells/mL. If there were greater than 10% dead
cells after trypsinizing, encapsulation was postponed. The gelation parameters were
consistent with hydrogel fabrication for rheological characterization (i.e. 70 kLux for
5-minutes via AmScope Cold-Light Source Haloid Lamp).
Encapsulating PANC-1 in UV crosslinked hydrogels was also accomplished in sy-
ringes with their tops cut off. The volume of the hydrogels and encapsulation densities
were maintained between UV- and visible-light hydrogels. Again, if there were greater
than 10% dead cells after trypsinizing, encapsulation was postponed. The gelation
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parameters were consistent with hydrogel fabrication for rheological characterization
(i.e. 5 mW/cm2 for 2-minutes via Blak-Ray XX-15M UV Bench Lamp).
Similar to culturing on TCPs, media was refreshed every 2-3 days, as needed.
Stiffening was generally accomplished overnight from Day 1 to Day 2 (e.g. encap-
sulation was on Day 0). In some cases, stiffening was delayed until Day 7, to allow
clustering of cells to occur.
3.6 Spheroid media preparation
Spheroid media was prepared following the procedure in [58]. Briefly, 20 ng/mL
endothelial growth factor (EGF) and fibroblast growth factor (FGF) were added to
100 mL high glucose DMEM:F12 with 1% P/S . Additionally, 2% N21-MAX and 1%
N2-MAX media supplements were added to the media.
3.7 Live/dead staining and imaging
To characterize the viability and morphology of encapsulated cells, live/dead stain-
ing was utilized. Calcein AM and Ethidium III was used for live and dead staining,
respectively. Hydrogels with encapsulated cells were transferred to new well plates
and washed 3x with DPBS for 5-minutes prior to the addition of staining solution.
Once staining solution was added, the gels were protected from light and incubated
for 1-hour on a stirring plate to allow the stain to diffuse. Subsequently, excess stain
was removed from the gels with another series of 3 5-minute washes with DPBS. Hy-
drogels were then transferred onto glass slides for imaging. Images were acquired via
LionHeart FX automated microscope and image analysis was conducted in ImageJ.
3.8 Drug responsiveness in encapsulated cells
To characterize drug resistance of encapsulated cells, gemcitabine was used. A
previously reported lethal dose, 50% (LD50) concentration of 1 µM gemcitabine was
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employed for drug studies [59], as well as 4 µM and 10 µM to see an increased cell
death profile. Cells were allowed to grow in hydrogels prior to stiffening, after which
gemcitabine was added to each well. Gemcitabine and media were refreshed daily
until the end of drug treatment, which lasted 4-days. To quantify metabolic activity
and viability, AB and live/dead staining was utilized, respectively. Morphology was
also monitored via live/dead staining. Imaging was conducted with LionHeart and
image analysis was conducted in ImageJ.
3.9 Immunofluorescence
To visualize CD44 expression on encapsulated cells, immunofluorescence was uti-
lized. Immediately following drug treatment, hydrogels were washed (2x) and cells
were fixed with 4% paraformaldehyde. Hydrogels were washed again (3x) and cells
were blocked and permeabilized with bovine serum albumin (BSA) and Triton-X-100
solution overnight at 4oC. The next day, BSA and Triton-X-100 solution was replaced
with primary antibody (i.e. rabbit anti-CD44), BSA, and Triton-X-100 solution and
stored at 4oC overnight. Hydrogels were then washed (3x) with BSA and Triton-X-
100 solution and stored at 4oC in secondary antibody (goat anti-rabbit-TR), BSA,
and Triton-X solution overnight, while being protected from light. Protecting hydro-
gels from light, they were washed (3x) and stained with 4’,6-diamidino-2-phenylindole
(DAPI). Following DAPI staining, hydrogels were washed again (3x) while being pro-
tected from light and subsequently imaged.
3.10 Statistical analysis
GraphPad Prism was the data analysis tool employed for all studies. Hydrogels
were prepared in triplicate for mechanical testing. Cell studies were repeated at least
once for verification of results. All statistical analysis was conducted using one-way
ANOVA with a Bonferroni post-test analysis. In summary, * represents p < 0.05 , **
represents p < 0.001, and *** represents p < 0.0001.
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4. RESULTS AND DISCUSSION
4.1 Tunable visible-light crosslinking of thiol-norbornene hydrogels
One of the goals of this study was to create a tunable visible-light initiated thiol-
norbornene primary hydrogel network to mimic the stiffness of healthy pancreatic
tissue. It is known that many factors, such as exposure time to light and concentration
of photo-initiator would influence the crosslinking densities of hydrogels. Thus, as seen
in Figure 4.1, the initial storage modulus of gelatin-based hydrogels was readily tuned
via modulation of visible light exposure time and the concentration of photoinitiator
(i.e. LAP) within the gel precursor solution.
Fig. 4.1. Effect of photoinitiator concentration and poly-
merization time on visible light initiated crosslinking of
Gel(B)NB (5 wt%) hydrogels. PEG4SH: 1 wt% (R=0.45); Visi-
ble light intensity: 70 kLux
Every hydrogel formed contained the same macromer content (Figure 4.1). The
initial storage modulus, and crosslinking density, was tuned as a function of exposure
time and LAP concentration (i.e. more exposure time or LAP resulted in an increased
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initial storage modulus). When using 1 mM LAP in the gel precursor, only the
highest exposure time formed a gel and it was soft (i.e. 170 Pa) and difficult to
handle. When using 2 mM LAP, gels formed under all exposure times. The lowest
storage modulus was 300 Pa and the highest was 2,200 Pa, for 2- and 6-minute
exposure time, respectively. When using 4 mM LAP, again, gels formed under each
exposure time. The storage modulus, of gels formed with 2-minutes of exposure time,
more than doubled (i.e. 1,150 Pa) when compared to those formed with 2-minutes
exposure time and 2 mM LAP. The highest storage modulus, from 6-minute exposure
time, had a more modest increase of 25%, which was not significant, when compared
to the gels formed with 2 mM LAP. A few conditions would lead to physiologically
relevant stiffness, when compared to healthy pancreatic tissue [17]. Naturally present
cell-attachment and MMP-degradable sites within this gelatin-based hydrogel system
make it highly attractive and biomimetic.
Another commonly used method to control the crosslinking density of hydrogel
networks lies within modulation of the concentrations of crosslinker. Thus, by manip-
ulating the R-value (i.e. [SH]:[NB]), the crosslinking densities of PEG-based hydrogels
were tuned (Figure 4.2).
Fig. 4.2. Controlling initial crosslinking density of PEG8NB
(3 wt%) hydrogels via tuning R-value (i.e., [SH]:[NB]). LAP: 4
mM; Visible light intensity: 70 kLux; Polymerization time: 5-minutes
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Crosslinking densities, and initial storage moduli, were tuned via maintaining a
constant concentration of NB-containing macromer and adjusting the concentration of
thiol-containing macromer. Thus, hydrogel crosslinking density correlates positively
to the R-value (between 0.33 and 1). Specifically, with 3-fold excess of NB to thiol
moiety (i.e., R=0.33), gels were formed with storage moduli of less than 1,000 Pa. At
a stoichiometric ratio of thiol and NB (i.e., R = 1), there was a significant increase
in storage moduli, reaching above 10 kPa. The hydrogel formed with an R-value of
0.33 is physiologically relating to healthy pancreatic tissue stiffness [17] and could be
considered biomimetic if it were tagged with cell-attachment and MMP-degradable
sequences [45].
4.2 Tunable crosslinking of hydrazone hydrogels
In addition to thiol-NB photopolymerization, hydrazone crosslinked primary hy-
drogel networks can also be used to present physiologically relevant stiffness. Due
to the spontaneous reactivity of this crosslinking, an initiator is not required for the
gelation. Thus, manipulation of macromer content was employed in efforts to tune
crosslinking density (Figure 4.3).
As shown in Figure 4.3, the storage modulus of hydrazone hydrogels increased as
the content of macromer increased (i.e., Gel(B)NB-CDH and PEG4pAld). Note that
in this chemistry, hydrogels were crosslinked by CDH-aldehyde reaction (Figure 1.5).
Maintaining a constant molar ratio of aldehyde to CDH and adjusting the macromer
content provided an efficient means to tune this systems stiffness, as indicated by
significant stiffness differences between the hydrogels with various macromer content.
Although this system requires no initiator, the resulting initial gel moduli were much
higher than what would be considered for a healthy tissue, when compared to healthy
pancreatic tissue (i.e., G’ 1000 Pa) [17].
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Fig. 4.3. Controlling initial crosslinking density of Gel(B)NB-
CDH hydrogels via tuning macromer concentration while
maintaining Q-value (i.e., [Ald]:[CDH]). PEG4pAld: 1.56, 2.34,
and 3.9 wt%, respectively; Q=0.5
4.3 Tunable crosslinking of UV-light thiol-norbornene hydrogels
Owing to the presence of dual functional groups, Gel(B)NB-CDH can be cross
linked either by hydrazone click chemistry or by thiol-NB photopolymerization. Sim-
ilar to tuning crosslinking density of visible-light initiated thiol-NB hydrogels, UV-
initiated gelation could be used to tune hydrogel modulus within the stiffness range of
healthy pancreatic tissue. In this gelatin-based hydrogel system, a constant R-value
of 0.5 (i.e. 2-fold excess NB-to-thiol) was utilized to allow for photo-click thiol-NB
based biomolecule-tagging or further stiffening. Although maintaining a constant R-
value was employed, the system still held potential to be tuned via concentration of
LAP in the precursor. In Figure 4.4, the effects of manipulating the precursor LAP
concentration is shown.
As seen in Figure 4.4, the crosslinking density of this hydrogel system increased
as a function of the concentration of LAP within the gel precursor solution. Each gel
formulation was identical, with the only difference being the concentration of LAP.
This provides another method for tuning the crosslinking density within the UV-light
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Fig. 4.4. Effect of photoinitiator concentration on UV
light initiated crosslinking of Gel(B)NB (5 wt%) hydrogels.
PEG4SH: 1 wt% (R=0.5); UV light intensity: 5 mW/cm2; Polymer-
ization time: 2-minutes
crosslinked thiol-norbornene primary network. The hydrogels formed with 1 and 2
mM LAP were slightly too soft and stiff, respectively, when compared to healthy
pancreatic tissue [17]. However, the hydrogels formed with 1.5 mM LAP mimicked
the stiffness of healthy pancreatic tissue well [17]. Due to the natural presence of
cell-attachment and MMP-degradable sequences within gelatin, this is an attractive,
biomimetic system.
4.4 Click Tz-NB reaction for temporally controlled stiffening of visible-
light hydrogels
Hydrogels were formed with excess click reactions with Tz for temporally con-
trolled stiffening. Utilizing one of the formulations of gelatin-based networks, stiffen-
ing with TMMs (either Hep-Tz or HA-Tz) was attempted (Figure 4.5).
Starting with the same hydrogel composition and similar storage moduli, the
hydrogels in Figure 4.5 were exposed to 0.5 wt% soluble HA-Tz or Hep-Tz for 24-
hours. After 24-hours of exposure, the storage moduli of the hydrogels did not change
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Fig. 4.5. Effect of TMM (0.5 wt%) on stiffening of Gel(B)NB
(5 wt%) hydrogels. PEG4SH: 1.5 wt% (R=0.45); LAP: 4 mM;
Visible light intensity: 70 kLux; Polymerization time: 5-minutes
significantly, suggesting that additional crosslinks did not occur. After some consid-
eration, it was thought that a potential issue could be that the NB groups were on
gelatin. Gelatin is a natural material that is charged and an irregularly structured.
The charged and irregularly structured nature of this material might inhibit Tz-NB
crosslinking. Thus, the same method of stiffening was explored with a PEG-based
hydrogel (Figure 4.6).
Unlike in gelatin-based networks, TMM stiffening was more effective in PEG-based
networks. This indicated that there is an issue causing hinderance of the click Tz-
NB reaction when NB is on gelatin (cause unknown), but not PEG. This being said,
PEG-based systems were further explored in efforts to tune the stiffening capacity
provided from TMMs. In Figure 4.7, the effect of R-value on the resulting stiffness
increases was explored.
As indicated with gelatin-based thiol-norbornene hydrogels, the initial storage
modulus (i.e. crosslinking density) could be tuned as a function of R-value. Physically,
this means that as the R-value increases, so does the number of crosslinks, up to a
theoretical 100% maximum achieved with an R-value of 1. Thus, it was expected
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Fig. 4.6. Effect of TMM (0.5 wt%) on crosslinking of PEG8NB
(3 wt%) hydrogels. DTT: 1.62 mM (R=0.45); LAP: 4 mM; Visible
light intensity: 70 kLux; Polymerization time: 5-minutes
Fig. 4.7. Controlling HA-Tz (0.5 wt%) stiffening of PEG8NB
(3 wt%) hydrogels via R-value manipulation. PEG4SH: 0.8,
1.2, 1.6, or 2.4 wt%, respectively; LAP: 4 mM; Visible light intensity:
70 kLux; Polymerization time: 5-minutes
that as the R-value increased, the stiffening effect (i.e. fold-increase in stiffness)
would decrease. As shown in Figure 4.7, this is exactly what was shown. There was
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a greater than 6-fold to 0-fold increase in stiffness as a result of 24-hour 0.5 wt%
HA-Tz stiffening, for R=0.33 and R=1, respectively. Interestingly, the maximum
stiffness achieved was in the R=0.67 case, which was slightly higher than the stiffness
of the non-stiffened or stiffened R=1 hydrogels. This suggests that Tz-NB crosslinks
provide a more rigid backbone than SH-NB crosslinks, likely due to the bulky Tz
structure, but this idea was not further explored.
Other methods for tuning the stiffening effects of this system, while maintaining
a constant macromer content, photo-initiator content, and R-value, included: (1)
manipulating the concentration of soluble TMM for stiffening and (2) manipulating
the substitution of Tz within the TMMs, while utilizing the same concentration of
TMM for stiffening. The results of (1) and (2) can be seen in Figures 4.8 and 4.9,
respectively.
Fig. 4.8. Tuning stiffening of PEG8NB (3 wt%) hydrogels
via manipulating PEG4Tz concentration. PEG4SH: 1.2 wt%
(R=0.5); LAP: 4 mM; Visible light intensity: 70 kLux; Polymerization
time: 5-minutes
Starting with the same macromer and photo-initiator content, as well as R-value,
yielded hydrogels that had similar moduli after initial crosslinking. However, when
the concentration of PEG4Tz was manipulated, the resulting degree of stiffening
became significantly different between groups, as shown in Figure 4.8. Although 0.5
34
Fig. 4.9. Tuning stiffening of PEG8NB (3 wt%) hydrogels via
manipulating Tz-substitution on Hep-Tz. PEG4SH: 0.8 wt%
(R=0.33); LAP: 4 mM; Visible light intensity: 70 kLux; Polymeriza-
tion time: 5-minutes
wt% and 1 wt% PEG4Tz stiffening did not result in statistically significant differences
in stiffening, this is very likely attributed to the vast reduction in geometry for the
1 wt% condition. The greater the stiffening, the smaller the hydrogels became, both
in thickness and in diameter. This caused practical issues when testing them on the
rheometer, as they were all initially fabricated with dimensions of 8 mm diameter
and 1 mm thickness, but after stiffening with 1 wt% PEG4Tz, the diameter and
thickness had nearly halved. This left large gaps between the rheometer base plate and
the rheometry head, meaning that the recorded stiffness values were underestimated
owing the smaller size of the gels compared to the testing geometry.
Additionally, manipulation of the Tz substitution within the TMMs resulted in
significantly different stiffening capabilities while using the same 0.5 wt% TMM, as
indicated in Figure 4.9. In low substitution Hep-Tz, there was a less than 4-fold
increase in stiffness. In mid substitution Hep-Tz, there was a less than 7-fold increase
in stiffness. In high substitution Hep-Tz there was a greater than 10-fold increase in
stiffness. Thus, via manipulation of the concentration of TMM (with the same substi-
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tution) or the substitution of Tz within the TMM (utilizing the same concentration
of TMM) tuning of stiffening was achieved within this system. However, because
this system is PEG-based, it would need to be further modified with cell-attachment
and MMP-degradable sequences to become biologically relevant. In lieu of this and
the understanding that click Tz-NB stiffening is possible within PEG-based, but not
gelatin-based hydrogels, a PEG-gelatin hybrid hydrogel system was fabricated, in
which temporally-based stiffening capabilities were explored, as shown in Figure 4.10
and Figure 4.11.
Fig. 4.10. Effect of TMM (0.5 wt%) on crosslinking of
PEG8NB (2 wt%) and Gel(B)NB (0.5 wt%) hydrogels.
PEG4SH: 0.9 wt% (R=0.5); LAP: 4 mM; Visible light intensity: 70
kLux; Polymerization time: 5-minutes
Utilizing a predominately PEG-based hydrogel for stiffening capabilities, while
including gelatin for cell-attachment and MMP-degradable sequences, stiffening with
HA-Tz and PEG4Tz was accomplished in a physiologically relevant manner. Addi-
tionally, it was proven that temporal control of stiffening is possible through simply
removing the hydrogels from solution containing TMMs (Figure 4.11). The initial
stiffness of the fabricated hydrogels were mimetic of healthy pancreatic tissue, while
the 0.5 wt% TMM stiffened hydrogels were mimetic of diseased pancreatic tissue [17].
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Fig. 4.11. Temporal control of stiffening of PEG8NB (2 wt%)
and Gel(B)NB (0.5 wt%) via PEG4Tz (0.9 wt%). PEG4SH:
0.9 wt% (R=0.5); LAP: 4 mM; Visible light intensity: 70 kLux; Poly-
merization time: 5-minutes
Thus, this system along with the method of stiffening was an attractive means to
mimic the progression of PDAC, in which matrix stiffness increases and there is an
increase in the presence of HA [20]. Verification that TMMs were the cause of stiff-
ening was confirmed qualitatively utilizing DMMB and Hep-Tz stiffening PEG-based
hydrogels, as shown in Figure 4.12. Specifically, DMMB selectively binds to sul-
fated groups, which are naturally present in heparin. When DMMB binds to sulfated
groups, it undergoes a color change from blue to pink. Thus, it was confirmed that
Hep-Tz was immobilized within the hydrogel due to the selective color change of the
stiffened hydrogel.
4.5 Dynamic stiffening of gelatin-based hydrogels via hydrazone crosslinks
Utilizing hydrogels formed with excess CDH for click reaction with aldehyde in
oxidized macromers, an additional dynamic stiffening method was explored. First, the
efficacy of oHA stiffening was explored with PEG-gelatin hydrogels initially formed
via hydrazone crosslinks (Figure 4.13). Again, although gelatin naturally has cell-
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Fig. 4.12. DMMB-stained PEG-based hydrogels. PEG4Tz
stiffening (left); Hep-Tz stiffening (right)
attachment and MMP-degradable sequences, the presence of NB left potential for
further modification of this system utilizing photo-click thiol-norbornene crosslinks
from thiol-containing modifiers.
Fig. 4.13. Effect of 74 kDa 20% oHA (0.5 wt%) on Gel(B)NB-
CDH (5 wt%) hydrogel crosslinking. PEG4pAld: 3.9 wt%
(Q=0.5)
Due to the reversible, viscoelastic nature of hydrazone crosslinks and their uti-
lization in shear-thinning, injectable, and self-healing hydrogels [34,48,55,60,61], loss
modulus changes were investigated along with storage modulus changes in the stiff-
ening process. Hydrogels initially formed with hydrazone crosslinks were relatively
stiff (i.e. 8 kPa storage modulus), when compared to healthy pancreatic tissue [17].
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There was significant stiffening from 24-hour exposure to 74 kDa 20% oHA. How-
ever, the degree of stiffening along with the initial modulus of this hydrogel made
it unattractive for mimicking the progression of PDAC. Utilizing a lower macromer
concentration as well as Q-value (i.e. [Ald]:[CDH]), stiffening capabilities of low MW
oHA (LMWoHA), mid MW oHA (MMWoHA), oDex, and PEG4Tz were explored,
as shown in Figure 4.14.
Fig. 4.14. Tuning stiffening of Gel(B)NB-CDH hydrogels via
different oxidized molecules (0.5 wt%) and PEG4Tz (0.5
wt%). PEG4pAld: 1.3 wt% (R=0.33); oHA (L):14.8 kDa; oHA
(M):74 kDa; oDex:100 kDa
Pre-stiffened hydrogels were all formed with the same macromer content and
therefore had similar initial moduli. LMWoHA, MMWoHA, and oDex all induced
significant stiffening for this hydrogel formulation. However, the stiffening was not
significantly different between these three groups. As expected, PEG4Tz was unable
to stiffen this gelatin-based hydrogel network, as seen in past results. The initial
and stiffened storage moduli of the hydrogels within the LMWoHA, MMWoHA, and
oDex groups were attractive because of their physiological relevance to healthy and
diseased pancreatic tissue, respectively [17]. Those within the LMWoHA and MM-
WoHA groups were particularly appealing, as the dynamic increases in both stiffness
and HA content mimic the progression of PDAC microenvironment [20]. However,
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these hydrogels, with initial networks prepared via click hydrazone chemistry, were
extremely sticky, difficult to handle, and became too soft for prolonged cell cultur-
ing experiments by the 3rd day. Therefore, primary networks formed from UV-light
initiated thiol-norbornene crosslinks and their ability to be controllably stiffened via
LMWoHA and MMWoHA were explored. The tunability of stiffening was explored
via manipulation of photo-initiator concentration within the gel precursor solution
(Figure 4.15) and the concentration of LMWoHA (Figure 4.16).
Fig. 4.15. Tuning oHA (0.5 wt%) stiffening of Gel(B)NB-CDH
(5 wt%) hydrogels via manipulation of LAP concentration.
PEG4SH: 1 wt% (R=0.5); UV light intensity: 5 mW/cm2; Polymer-
ization time: 2-minutes
Similar to increasing the R-value of hydrogels in previous experiments, increas-
ing the concentration of LAP within the gel precursors ultimately led to increased
crosslinking density between thiol and norbornene moieties. Due to this, it was ex-
pected and observed that the initial storage moduli for hydrogels would be a function
of LAP concentration (Figure 4.15). However, in this system the degree of stiffening
did not rely on excess NB, as it did in the dynamically stiffened Tz-NB system. Thus,
independent of LAP concentration, there was a 2-fold increase in stiffness due to 24-
hour incubation with 0.5 wt% LMWoHA or MMWoHA. Increasing the concentration
of oHA from 0.5 to 1 wt% did not significantly affect the degree of stiffening (Figure
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Fig. 4.16. Effect of varied oHA concentrations on Gel(B)NB-
CDH (5 wt%) hydrogel crosslinking. PEG4SH: 1 wt% (R=0.5);
UV light intensity: 5 mW/cm2; Polymerization time: 2-minutes
4.16). In both conditions, there is excess aldehyde compared to CDH. However, due
to the irregularity of the naturally derived materials, it was considered that there
would be a difference in stiffening when creating conditions of greater excess. This
was not the case.
4.6 Cytotoxicity of HA derivatives
There were two dynamic stiffening chemistries (i.e. Tz-NB and hydrazone click
chemistries) utilized in this study that could mimic the progression of PDAC. How-
ever, cytotoxicity is always a concern when introducing chemically modified molecules
to cells in culture. Thus, cytotoxicity studies with PANC-1 and HA-Tz or oHA were
conducted, in which the maximum concentration utilized was the concentration that
would (generally) be used for stiffening. The results of the cytotoxicity studies with
HA-Tz or oHA can be seen in Figure 4.17 or 4.18, respectively.
It is clear that HA-Tz has a detrimental effect on PANC-1 cells at the concen-
tration intended for stiffening of hydrogels with encapsulated cells (i.e. 0.5 wt%).
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Fig. 4.17. Effect of various HA-Tz concentrations on PANC-1
metabolic activity
Fig. 4.18. Effect of various oHA concentrations on PANC-1
metabolic activity
The LD50 concentration is roughly 10-fold lower than the concentration of HA-Tz
that would be used for dynamic stiffening and mimetics of PDAC progression. On
the other hand, the LD50 concentration of LMWoHA was not reached when utilizing
concentrations up to the dynamic stiffening concentration. Thus, oHA was deemed
the appropriate chemical tool for mimicking the progression of PDAC.
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4.7 PANC-1 encapsulation, viability, and morphology analysis in PDAC-
mimetic hydrogels
Although HA-Tz was deemed to be cytotoxic in 2D, there was potential that the
effects in a 3D setting would be different. Utilizing a PEG-gelatin hydrogel, PANC-1
was encapsulated and experienced PDAC-mimetics through dynamic stiffening and
HA accumulation (Figure 4.19).
Fig. 4.19. Effect of culture mediums and stiffening methods
on PANC-1 cell viability in PEG8NB (2 wt%) and Gel(B)NB
(0.5 wt%) hydrogels. PEG4SH: 0.9 wt% (R=0.5); LAP: 4 mM;
Visible light intensity: 70 kLux; Polymerization time: 5-minutes;
TMM: 0.5 wt%; Soluble HA: 0.5 wt%; 24-hour stiffening occurred
7-days after encapsulation; Live (green) stain: Calcien AM; Dead
(red) stain: Ethidium III
Hydrogel stiffening was initiated on Day 7 with 0.5 wt% HA-Tz or PEG4Tz. After
Tz-mediated stiffening, soluble LMWHA was introduced to the PEG4Tz stiffened
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gels to mimic stiffening with presence of HA (although the HA in this case was
soluble and not immobilized, like HA-Tz was). Additionally, there was a side-by-side
comparison of the cells grown in regular media (RM) or spheroid media (SM). SM
results in tumorsphere formation enriched with CSCs that are less metabolically active
in response to stressors and more resistant to chemotherapeutics, such as GEM [58].
Regardless of the culture medium, HA-Tz had a detrimental effect on the viability
and size of cells as early as 2 days after stiffening. PEG4Tz-stiffened gels also had
more dead cells than the non-treated control did, as well as smaller spheroids, but
they continued to grow past Day 14. Interestingly, PEG4Tz appeared to be less
cytotoxic than HA-Tz. Nonetheless, HA-Tz was verified to be extremely cytotoxic and
detrimental to encapsulated cells, at concentrations intended for hydrogel stiffening,
and was moved on from.
Next, utilizing another PEG-gelatin hydrogel, PANC-1 was encapsulated and the
system was dynamically stiffened via 0.5 wt% LMWoHA or MMWoHA for mimetics
of PDAC progression. In Figure 4.20, the viability and morphology results from Day
1 stiffening of the PEG-gelatin system are shown.
Drastically different than 0.5 wt% HA-Tz stiffening, 0.5 wt% LMWoHA or MM-
WoHA stiffening did not result in different levels of viability qualitatively (live/dead)
or quantitatively (alamarblue). Additionally, after stiffening there was not a signifi-
cant difference in spheroid size. Due to the sticky nature of these hydrogels and their
relatively quick degradation, they became too difficult to handle by the 5th day of
encapsulation. Thus, an increased concentration of LAP (i.e. 1.5 mM) was utilized
to form the same composition of hydrogel for increased integrity and prolonged cell
study potential. Stiffening was accomplished via MMWoHA at concentrations of 0.5
or 1 wt% (Figure 4.21).
Utilizing 1.5 mM LAP in the gel precursor, as opposed to 1 mM LAP, increased
the longevity of these hydrogels and thus their cell culture capabilities. After 24-hour
stiffening with 0.5 or 1 wt% LMWoHA, gels were imaged. Additionally, 4- and 7- days
after stiffening was completed (Day 6 and 9, respectively), these gels were imaged.
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Fig. 4.20. Live/dead staining (A), metabolic activity (B), and
spheroid sizes (C) of PANC-1 in Gel(B)NB-CDH (5 wt%)
hydrogels following oHA (0.5 wt%) stiffening. PEG4SH: 1
wt% (R=0.5); LAP: 1 mM; UV light intensity: 5 mW/cm2; Polymer-
ization time: 2-minutes. LMWoHA: 14.8 kDa; MMWoHA: 74 kDa;
24-hour stiffening occurred 1-day after encapsulation; Live (green)
stain: Calcien AM; Dead (red) stain: Ethidium III; images taken and
alamarblue conducted on Day 2
On the day stiffening was completed (Day 2), there was no significant difference in
spheroid size or viability. By the 6th day (i.e. 4-days after stiffening), there was a
significant difference between the sizes of the spheroids in the gels that were stiffened
by 0.5 or 1 wt% LMWoHA. By the 9th day (i.e. 7-days after stiffening), there was
no longer a significant difference in spheroid size between the stiffened groups.
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Fig. 4.21. Live/dead staining (A) and spheroid sizes (B) of
PANC-1 in Gel(B)NB-CDH (5 wt%) hydrogels following
stiffening with oHA (0.5 or 1 wt%). PEG4SH: 1 wt% (R=0.5);
LAP: 1.5 mM; UV light intensity: 5 mW/cm2; Polymerization time:
2-minutes; 24-hour stiffening occurred 1-day after encapsulation (Day
2)
4.8 Response of encapsulated PANC-1 to chemotherapeutics in PDAC-
mimetic hydrogels
PEG-gelatin hybrid hydrogels were stiffened via 1 wt% MMWoHA on the 7th day
of encapsulation, followed by initiation of 1 µM gemcitabine treatment on the 8th day.
Drug treatment endured for 4-days (i.e. until Day 12). Before and after stiffening
and drug treatment, alamarblue was conducted. A baseline for metabolic activity
was quantified via alamarblue before stiffening and drug treatment. The results from
this study are shown in Figure 4.22.
On Day 7, encapsulated PANC-1 were viable and had formed spheroids. Overnight
stiffening with 1 wt% MMWoHA resulted in a significant decrease in metabolic ac-
tivity, according to alamarblue assay. Following alamarblue assay, on Day 8, 1 µM
GEM was added to wells with non-stiffened and stiffened gels. Control non-stiffened
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Fig. 4.22. Live/dead staining (A and C), metabolic activity
(B and E), and spheroid sizes (D) of PANC-1 in Gel(B)NB-
CDH (5 wt%) hydrogels following oHA (1 wt%) stiffening
and GEM (1 µM) treatment. PEG4SH: 1 wt% (R=0.5); LAP:
1.5 mM; UV light intensity: 5 mW/cm2; Polymerization time: 2-
minutes. 24-hour stiffening occurred 7-days after encapsulation; 4-
day GEM treatment started immediately after stiffening; metabolic
activity determined via alamarblue following stiffening (Day 8) and
GEM treatment (Day 12); Live (green) stain: Calcien AM; Dead (red)
stain: Ethidium III. -S -G: non-stiffened and non-treated; -S +G: non-
stiffened and GEM-treated; +S -G: HA-stiffened and non-treated; +S
+G: HA-stiffened and GEM-treated
and stiffened conditions were not treated with GEM. After 4-days of GEM treat-
ment, live/dead and alamarblue assay were completed. By the end of GEM treat-
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ment (Day 12), PANC-1 spheroids in all conditions had insignificant size differences
and viabilities (non-stiffened/GEM-treated hydrogels were too soft and unworkable).
Metabolic activities in non-stiffened/non-treated and non-stiffened/treated groups
were significantly different. However, metabolic activities in stiffened/non-treated
and stiffened/GEM-treated groups were not significantly different. This suggests
that the synergistic effect of stiffening with HA increases drug resistance. Although
there was a decrease in metabolic activity, the viability of imaged cells was similar.
Therefore, another experiment was conducted in which the concentration of GEM was
increased. Additionally, the concentration of LAP in the gel precursor was increased
to 2 mM, raising the non-stiffened and stiffened moduli by greater than 40%. This
ensured that the gels would remain workable for the duration of the study.
Immediately following stiffening (Day 2), there was not a significant difference
between spheroid sizes or viabilities between the control and the stiffened conditions.
Two days after the gels were stiffened (Day 4), 4-day GEM treatment started. Imme-
diately following GEM treatment (Day 8), spheroids in the non-stiffened/non-treated
gels were significantly larger than all other conditions; there was no significant differ-
ence between spheroid sizes in the remaining conditions. The viability of encapsulated
cells was comparable between all conditions. Not surprisingly, there were more dead
cells within the GEM-treated gels than the non-treated gels. Additionally, metabolic
activity of cells within the non-stiffened/non-treated gels were significantly differ-
ent than those within the PEG-stiffened/GEM-treated gels; there was no significant
difference between metabolic activities in any other conditions.
Binding interactions between HA and CD44 activate and regulate several cellular
signaling processes which are key in the mediation of tumor progression, metastasis,
and chemoresistance [62]. To investigate whether HA binding interactions played a
role in drug resistance, encapsulated cells were fixed following GEM treatment and
subsequently stained for CD44. An increase in CD44 expression for cells in HA-
stiffened/GEM-treated hydrogels would suggest a vital role of HA-binding in drug
resistance. Interestingly, CD44 expression was the highest in the non-stiffened/non-
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Fig. 4.23. Day 2 (A) and Day 8 (B) live/dead staining of en-
capsulated PANC-1; Day 8 spheroid size (C) and metabolic
activity (D) of encapsulated PANC-1 following stiffening and
drug treatment in Gel(B)NB-CDH (5 wt%) hydrogels; Stiff-
ening via oHA (0.5 wt%) or PEG4pAld (0.5 wt%); 4 µM
GEM treatment. PEG4SH: 1 wt% (R=0.5); LAP: 2 mM; UV
light intensity: 5 mW/cm2; Polymerization time: 2-minutes; 24-hour
stiffening occurred 1-day after encapsulation (Day 2); 4-day GEM
treatment started 2-days after stiffening (Day 4); metabolic activity
determined via alamarblue assay following GEM treatment (Day 8);
Live: green; Dead: red; - -: non-stiffened and non-treated; - +: non-
stiffened and GEM-treated; +HA +: HA-stiffened and GEM-treated;
+PEG +: PEG-stiffened and GEM-treated
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Fig. 4.24. DAPI and CD44 stained PANC-1 encapsulated in
Gel(B)NB-CDH (5 wt%) hydrogels following stiffening and
GEM treatment; Stiffening via oHA (0.5 wt%) or PEG4pAld
(0.5 wt%); 4 µM GEM treatment. PEG4SH: 1 wt%; LAP: 2
mM; UV light intensity: 5 mW/cm2; Polymerization time: 2-minutes;
24-hour stiffening occurred 1-day after encapsulation (Day 2); 4-day
GEM treatment started 2-days after stiffening (Day 4); DAPI: blue;
CD44: red
treated condition. Very little CD44 was expressed in the remaining, GEM-treated,
conditions. GEM may play an antagonistic role in CD44 expression, which would
be a novel discovery. Therefore, a similar experiment was conducted in which the
GEM concentration was increased further, to see more significant cell death, as well
as introducing oHA-stiffened/non-treated and PEG-stiffened/non-treated groups.
Immediately following stiffening (Day 2), spheroid sizes in the stiffened groups
were similar, but significantly different than the non-stiffened group. Again, 4-day
GEM treatment started two days after stiffening (Day 4). Immediately following
GEM-treatment (Day 8), spheroid sizes in the non-stiffened/non-treated and HA-
stiffened
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Fig. 4.25. Day 2 (A) and Day 8 (B) live/dead staining of en-
capsulated PANC-1; Day 2 (C) and Day 8 (D) spheroid sizes
of PANC-1; Gel(B)NB-CDH (5 wt%) hydrogels stiffened via
oHA (0.5 wt%) or PEG4pAld (0.25 wt%); treated with 10
µM GEM. PEG4SH: 1 wt% (R=0.5); LAP: 2 mM; UV light inten-
sity: 5 mW/cm2; Polymerization time: 2-minutes. 24-hour stiffening
occurred 1-day after encapsulation (Day 2); 4-day GEM treatment
started 2-days after stiffening (Day 4); metabolic activity determined
via alamarblue following GEM treatment (Day 8); Live: green; Dead:
red; - +: non-stiffened and GEM-treated; +HA: HA-stiffened; +PEG:
PEG-stiffened; +HA -: HA-stiffened and non-treated; +HA +: HA-
stiffened and GEM-treated; +PEG -: PEG-stiffened and non-treated
+PEG +: PEG-stiffened and GEM-treated
/non-treated groups were significantly larger than those in all other groups. There
was no significant difference between spheroid sizes in PEG-stiffened/non-treated and
PEG-stiffened/GEM-treated groups. Interestingly, the most dead cells were in the
non-stiffened/GEM-treated and PEG-stiffened/GEM-treated conditions. It is clear
that HA-stiffening allows cells to continue to grow normally, whereas PEG-stiffening
does not. Additionally, cells within HA-stiffened/GEM-treated gels had similar via-
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bility to those within HA-stiffened/non-treated gels. There was a clear difference be-
tween viabilities in PEG-stiffened/non-treated and PEG-stiffened/GEM-treated con-
ditions. Contrarily, when PANC-1 was cultured in stiff hydrogels and treated with an
antitumor peptide drug, in the absence of HA, there was extremely low viability [63].
This suggests that HA-stiffening promotes PDAC cell growth and survival, even in
the presence of chemotherapeutics, similar to the effects of matrix stiffening and HA
accumulation in PDAC progression.
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5. CONCLUSION AND RECOMMENDATION FOR
FUTURE WORK
In this study, dynamically tunable hydrogels mimicking the development of
PDAC (i.e. increased matrix stiffness and HA accumulation) were developed. Specif-
ically, (1) PEG-gelatin hybrid hydrogel initially formed with photo-click thiol-
norbornene crosslinks containing unreacted norbornene for further click crosslinking
with tetrazine-modified HA and (2) PEG-gelatin hybrid hydrogel initially formed
with click hydrazone or photo-click thiol-norbornene crosslinks containing unreacted
carbohydrazide for further crosslinking with oxidized HA. It was determined that
tetrazine-modified HA is cytotoxic at concentrations below that intended for hydro-
gel stiffening. Thus, oxidized HA was utilized with PEG-gelatin hybrid hydrogels
containing excess carbohydrazide for PDAC-mimetics. This system was utilized for
PANC-1 cell encapsulation and did not result in significantly different levels of via-
bility or metabolic activity, when stiffened with 0.5 wt% LMWoHA or MMWoHA.
Furthermore, due to stiffening there was an increase in drug resistance for cells encap-
sulated in hydrogels stiffened with oxidized HA. This resistance mimics the behavior
of PDAC cells in their natural environment during disease progression and, therefore,
is an attractive culture platform for studying the interactions of PDAC cells with
their environment and the resistance of drugs.
Moving forward, it is recommended that a system is developed in which HA is
initially present and is further concentrated due to stiffening. This would more ac-
curately mimic the progression of PDAC, as healthy pancreatic tissue has HA as
well. Another benefit of using dynamic hydrazone bonds are their innate reversibility
and viscoelasticity. Thus, working to characterize and tune not only stiffness, but
viscoelasticity is of great interest, considering the viscoelastic nature of tissue. Addi-
tionally, stiffening with oxidized HA should be accomplished with concentrations less
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than 1 wt% because 0.5 and 1 wt% oxidized HA stiffen the network similarly and 1
wt% makes the encapsulated cells less metabolically active. To investigate how impor-
tant HA is in increasing drug resistance, blocking HA binding with a peptide could be
explored. Additionally, comparison of CD44 expression between HA-stiffened/non-
treated and HA-stiffened/GEM-treated groups could provide insight into the impor-
tance of HA-CD44 binding interactions. Alongside drug studies, detection of EMT
markers, such as N-cadherin on PDAC cells, or the expression of αSMA in PSCs
could be visited, as they are generally correlated with worsened prognosis and more
invasive cancers.
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